- Home
- ALDX
as 04-11-2025 4:00pm EST
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 398.3M | IPO Year: | 2014 |
| Target Price: | $9.67 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $7.20 | Next Earning Date: | 05-01-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aldeyra Therapeutics Inc. (ALDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 3 '25 | Sell | $1.42 | 3,400,000 | $4,828,000.00 | 5,875,851 |
Latest Aldeyra Therapeutics Inc. News
ALDX Breaking Stock News: Dive into ALDX Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
3 Promising Penny Stocks With Market Caps Under $600M
MT Newswires
10 days ago
Top Midday Decliners
Investopedia
10 days ago
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter
MT Newswires
10 days ago
Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease Treatment - Shares Slump Pre-Bell
Business Wire
11 days ago
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Simply Wall St.
a month ago
High Growth Tech Stocks To Watch In The US March 2025
Business Wire
a month ago
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
Business Wire
2 months ago
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Compare ALDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALDX Aldeyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.